Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dupixent Heralds The Age Of Biologics In COPD

Executive Summary

A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.

You may also be interested in...



CEO Hudson: No Rust On Sanofi Launch Engine

Some analysts have expressed concern in the past about the French drugmaker’s product launchpad but CEO Paul Hudson has dismissed such claims, pointing to the spectacular lift off of Beyfortus.

What Verona Needs To Make COPD Drug Ensifentrine A Success

Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.

Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD

Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel